Excellergy key facts
- Developer of protein therapeutics designed to combat severe allergic diseases.
- Excellergy’s last known valuation is $122.2M.
- It has raised $79.8M; the latest was Early Stage VC ($72.2M) in Aug 2024.
- Notable investors include Samsara BioCapital, Red Tree Venture Capital, Decheng Capital.
- Status: Privately Held (backing).
Who backs Excellergy
3- ·Watch Excellergy: the Monday email on marks, rounds and moves
Excellergy funding rounds
No funding rounds for Excellergy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Excellergy valuation
Excellergy's last known valuation is $122 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Excellergy investors
3 investors are on record for Excellergy, including Samsara BioCapital, Red Tree Venture Capital and Decheng Capital.
About Excellergy
Developer of protein therapeutics designed to combat severe allergic diseases. The company offers specialized expertise in IgE biology and anti-IgE molecular pharmacology, enabling patients with severe allergies to experience improved quality of life.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2020
- Employees
- 7
- Website
- excellergy.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Excellergy’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.